Home
Company
About us
Management
Board of Directors
Scientific Advisory Board
Partnerships
Partnerships
Nox Science
NOX Enzymes
NADPH Oxidase
NOX Enzyme Family
NOX Expression
NOX and Disease
Oxidative Stress and Disease
Physiological Functions of NOX
Fibrotic diseases
Neurodegenerative diseases
Cardiovascular diseases
Publications
Pipeline
GKT831
GKT771
Research programs
Investors
Stock information
Analyst coverage
Contribution project
Press release
Project presentation
Documentation
Shareholders general meeting
Press releases
2019
2018
2017
2016
2015
2014
Events and presentations
Regulated information
Financial information
2019
2018
2017
2016
2015
2014
Other regulated information
2019
2018
2017
2016
2015
2014
Governance
OCABSA warrants
Shareholder information
Shareholders’ meetings
2019
AGE of january 2019
2018
2017
AGM of June 15, 2017
AGM of February 28, 2017
2016
2015
2014
Agenda
News and Events
Press releases
Events and presentations
Media
Press clippings
Interviews
Contacts
News
See all news
Prev
Next
2019-05-02 - 07:00
Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT83...
2019-05-01 - 18:00
Genkyotex Conference Call at 2pm Paris time on 2nd MayGenkyotex Confer...
2019-04-25 - 18:00
Genkyotex provides corporate update and reports cash position at March...
2019-04-08 - 07:00
Genkyotex to present updated interim results from Phase 2 trial of GKT...
2019-03-29 - 07:00
Genkyotex reverse stock split takes effect
2019-03-11 - 07:00
Genkyotex Announces Completion of 24-Week Treatment Period of its Phas...
2019-02-28 - 19:00
Genkyotex announces 2018 annual financial results and provides corpora...
2019-02-27 - 07:00
Launch of the reverse stock split of Genkyotex shares
Events
See all events
2019-05-10 - 09:00
Investor Presentation May 2019
2019-05-02 - 13:00
Phase 2 trial of GKT831 in patients with primary biliary cholangitis ...
2019-04-24 - 14:00
ILC2019 Presentation – GKT831 Phase 2 in PBC
2018-11-05 - 15:00
Management presentation on positive interim Phase 2 results in PBC
